Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 August;64(4) > Minerva Cardioangiologica 2016 August;64(4):462-72

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

REVIEWS  NEW BIORESORBABLE TECHNOLOGY IN INTERVENTIONAL CARDIOLOGY 

Minerva Cardioangiologica 2016 August;64(4):462-72

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology

Wijnand K. DEN DEKKER, Robert J. VAN GEUNS, Roberto DILETTI

Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands


PDF


The everolimus eluting bioresorbable vascular scaffold (BVS) represents a novel technology and a novel paradigm for treatment of coronary artery disease, with the potential of improving the long-term clinical outcomes after complete bioresorption. The increasing amount of clinical data is adding in a gradual understanding of the appropriate implantation technique, but long-term results after BVS implantation are sparse. In addition, concern related to a possible increased rate of scaffold thrombosis has recently risen. The present article reviews the current status of knowledge on bioresorbable vascular scaffold from the preclinical phase and the first-in-man experience to the recently reported large randomized trials. Challenging subsets are discussed as well as possible factors impacting on the occurrence of thrombotic events, particularly focusing on clinical outcomes reported in the longest follow-ups currently available.

top of page